Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 215-223

  Roth, Joshua A ^a   Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biliary tract cancer; Cisplatin; Cost effectiveness; Cost utility; Economic; Gemcitabine

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CISPLATIN; CLINDAMYCIN; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ERYTHROPOIETIN;

ADD ON THERAPY; ADVANCED CANCER; AFEBRILE NEUTROPENIA; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FOLLOW UP; HEALTH CARE COST; HUMAN; INFECTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MEDICAL FEE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROBABILISTIC SENSITIVITY ANALYSIS; PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84863872146     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9242-0     Document Type: Article

References (33)

1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-82.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;13:415-23.
3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353-7. (Pubitemid 32496970)
4. Hopfner M, Schuppan D, Scherubl H. Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol. 2008;14(46):7021-32.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V.1.2010.
6. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-25. (Pubitemid 38738341)
7. Zhu AX, El-Khoueiry A, Llovet JM. Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res. 2008;3(5):S28-36.
8. Wolpin BM, Mayer RJ. A step forward in the treatment of advanced biliary tract cancer. N Engl J Med. 2010;362:1335-7.
9. Glimelius B, Hoffman K, Sjodén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600. (Pubitemid 26285639)
10. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005;16(2):ii93-6. (Pubitemid 40908942)
11. Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Perez-Garcia J, et al. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Curr Opin Oncol. 2009;21:374-80.
12. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomized phase II study: the UK ABC-01 Study. Br J Cancer. 2009;101:621-7.
13. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small- cell lung cancer. J Clin Oncol. 2008;26:3543-51.
14. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 Study. Br J Cancer. 2009;101:621-7.
15. Hall FM. Cisplatin plus gemcitabine for biliary tract cancer. N Engl J Med. 2010;363:192-3.
16. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
17. Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for advanced hepatocellular carcinoma: evidence review group report. Health Technol Assess. 2010;14(1):17-21.
18. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630-41.
19. Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manage Care Pharm. 2009;15 (8):669-82.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer and Chemotherapy-Induced Anemia. V.2.2011.
21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. V.2.2009.
22. Dobrez D, Cella D, Packard AS, Lai JS, Nickolov A. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy-General. Value Health. 2007;10 (4):266-72. (Pubitemid 47077251)
23. Center for Medicare and Medicaid Services. Manufacturer average sales price data. Baltimore: Center for Medicare and Medicaid Services; 2009.
24. Johns Hopkins Point-of-Care Information Technology Center. Available from: http://www.hopkins-aids.edu/drug/ [Accessed: June 15, 2010].
25. Center for Medicare and Medicaid Services. Physician free schedule and acute inpatient prospective payment system. Baltimore: Center for Medicare and Medicaid Services; 2009.
26. Avritscher EBC, Cantor SB, Shih YCT, Escalante CP, Rivera E, Elting LS. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer. 2004;12:531-6. (Pubitemid 38931687)
27. U.S. Department of Labor, Bureau of Labor and Statistics. Occupational Employment Statistics. Available from: http://www.bls.gov [Accessed: June 15, 2010].
28. Ubel PA. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-41. (Pubitemid 36898950)
29. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness. Health Econ. 2010;19(4):422-37.
30. Glimelius B, Hoffman K, Graf W, Haglund U, Nyrén O, Påhlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6(3):205-7.
31. Norum J, Angelsen V. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. J Chemother. 1995;7(5):455-9.
32. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355 (10):983-91. (Pubitemid 44343542)
33. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25 (19):2747-54. (Pubitemid 47123183)